SURVANTA (beractant)
LUNG SURFACTANTS · RESPIRATORY DISTRESS SYNDROME IN THE NEWBORN ·+1
ABBOTT
Drug class
Lung Surfactants
Lung surfactants, also referred to as pulmonary surfactants, are a therapeutic class of surface-active lipoprotein preparations formulated from natural animal extracts or synthetic components. Read more about Lung Surfactants
3 drugs in this class 3 manufacturers
Drugs in Lung Surfactants
INFASURF (calfactant)
LUNG SURFACTANTS · RESPIRATORY DISTRESS SYNDROME IN THE NEWBORN ·+1
ONY, INC.
CUROSURF (poractant alfa)
LUNG SURFACTANTS · RESPIRATORY DISTRESS SYNDROME IN THE NEWBORN
CHIESI USA, INC
Filter & compare in the drug finder →
Opens the drug finder with Lung Surfactants preselected. Add indication or manufacturer filters there.
Lung surfactants, also referred to as pulmonary surfactants, are a therapeutic class of surface-active lipoprotein preparations formulated from natural animal extracts or synthetic components.
They act by lowering surface tension at the alveolar air-liquid interface, which stabilizes the alveoli against end-expiratory collapse, improves lung compliance, and enhances respiratory gas exchange.
Clinically, these agents are primarily indicated for the prevention and rescue treatment of respiratory distress syndrome in premature infants with endogenous surfactant deficiency.
-
rxlist.com
Lung surfactants, also referred to as pulmonary surfactants, are a therapeutic class of surface-active lipoprotein preparations formulated from natural animal extracts or synthetic components
-
nih.gov
Lung surfactants, also referred to as pulmonary surfactants, are a therapeutic class of surface-active lipoprotein preparations formulated from natural animal extracts or synthetic components Clinically, these agents are primarily indicated for the prevention and rescue treatment of respiratory distress syndrome in premature infants with endogenous surfactant deficiency
-
fda.gov
They act by lowering surface tension at the alveolar air-liquid interface, which stabilizes the alveoli against end-expiratory collapse, improves lung compliance, and enhances respiratory gas exchange
-
fda.gov
They act by lowering surface tension at the alveolar air-liquid interface, which stabilizes the alveoli against end-expiratory collapse, improves lung compliance, and enhances respiratory gas exchange
-
nih.gov
They act by lowering surface tension at the alveolar air-liquid interface, which stabilizes the alveoli against end-expiratory collapse, improves lung compliance, and enhances respiratory gas exchange Clinically, these agents are primarily indicated for the prevention and rescue treatment of respiratory distress syndrome in premature infants with endogenous surfactant deficiency
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and rescue treatment of respiratory distress syndrome in premature infants with endogenous surfactant deficiency
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.